Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.37 |
| ▸ | FEN1 | P39748 | 2/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ANO1 | Q5XXA6 | 9/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL268950 | 0.95 | POLB (0.45) | POLBAPEX1ALOX5APFEN1SMN1; SMN2 | |
| SCHEMBL268084 | 0.94 | POLB (0.41) | POLBAPEX1ALOX5APFEN1ALPL | |
| SCHEMBL269090 | 0.93 | POLB (0.39) | POLBAPEX1ALOX5APFEN1ALPL | |
| Hydrochloric Acid SCHEMBL268978 | 0.92 | POLB (0.38) | POLBAPEX1ALOX5APFEN1ALPL | |
| SCHEMBL267905 | 0.89 | ANO1 (0.42) | POLBAPEX1ALOX5APFEN1SMN1; SMN2 | |
| SCHEMBL267895 | 0.89 | ANO1 (0.46) | POLBAPEX1ALOX5APFEN1SMN1; SMN2 | |
| SCHEMBL270158 | 0.89 | DPP4 (0.40) | POLBAPEX1ALOX5APFEN1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL270358 | 0.88 | ANO1 (0.45) | POLBAPEX1ALOX5APFEN1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL270538 | 0.88 | ANO1 (0.45) | POLBAPEX1ALOX5APFEN1SMN1; SMN2 | |
| SCHEMBL269863 | 0.88 | ANO1 (0.45) | POLBAPEX1ALOX5APFEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133907-B2 | Type II diabetes, obesity, hyperglycemia and a lipid disorder selected from dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL and high LDL; additionally comprising metformin | ELI LILLY AND COMPANY (US) | 2012-03-13 | — | — | US | disclosed |
| EP-1912946-B1 | PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS | LILLY CO ELI (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080214616-A1 | Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors | ELI LILLY AND COMPANY | 2008-09-04 | — | — | US | disclosed |
| EP-1912946-A1 | PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS | Eli Lilly and Company (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007015767-A1 | PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214616-A1 | Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors | DPP4, DPP3, DPP7 | POLB 3975/4885APEX1 3527/4885ALOX5AP 3715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.